Published in Nat Cell Biol on March 14, 2004
AKT/PKB signaling: navigating downstream. Cell (2007) 31.26
Virus-free induction of pluripotency and subsequent excision of reprogramming factors. Nature (2009) 9.29
Myc's broad reach. Genes Dev (2008) 7.56
The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A (2004) 5.37
Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature (2005) 4.97
The Trithorax group protein Lid is a trimethyl histone H3K4 demethylase required for dMyc-induced cell growth. Genes Dev (2007) 2.57
Tumour maintenance is mediated by eNOS. Nature (2008) 2.52
Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci U S A (2007) 2.34
Oncogenic PIK3CA-driven mammary tumors frequently recur via PI3K pathway-dependent and PI3K pathway-independent mechanisms. Nat Med (2011) 2.34
PVT1 dependence in cancer with MYC copy-number increase. Nature (2014) 2.13
The tumor suppressor PP2A Abeta regulates the RalA GTPase. Cell (2007) 2.10
AMBRA1 links autophagy to cell proliferation and tumorigenesis by promoting c-Myc dephosphorylation and degradation. Nat Cell Biol (2014) 2.06
Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol (2006) 2.00
Prolyl isomerase Pin1 as a molecular switch to determine the fate of phosphoproteins. Trends Biochem Sci (2011) 1.98
Wilms tumor 1 (WT1) regulates KRAS-driven oncogenesis and senescence in mouse and human models. J Clin Invest (2010) 1.98
Physiological regulation of Akt activity and stability. Am J Transl Res (2010) 1.95
Myc proteins as therapeutic targets. Oncogene (2010) 1.88
Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. Cancer Cell (2013) 1.85
Inhibition of c-Myc activity by ribosomal protein L11. EMBO J (2007) 1.78
Inhibition of phosphatidylinositol 3-kinase destabilizes Mycn protein and blocks malignant progression in neuroblastoma. Cancer Res (2006) 1.70
Sphingosine analogue drug FTY720 targets I2PP2A/SET and mediates lung tumour suppression via activation of PP2A-RIPK1-dependent necroptosis. EMBO Mol Med (2012) 1.68
MYC and Breast Cancer. Genes Cancer (2010) 1.66
Fbw7/hCDC4 dimerization regulates its substrate interactions. Cell Div (2007) 1.64
A TRAIL receptor-dependent synthetic lethal relationship between MYC activation and GSK3beta/FBW7 loss of function. Proc Natl Acad Sci U S A (2005) 1.64
Cellular transformation by Simian Virus 40 and Murine Polyoma Virus T antigens. Semin Cancer Biol (2009) 1.63
Modeling breast cancer in vivo and ex vivo reveals an essential role of Pin1 in tumorigenesis. EMBO J (2004) 1.62
FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ (2011) 1.59
Mitochondrial dysfunction in cancer. Front Oncol (2013) 1.57
Phosphorylation stabilizes Nanog by promoting its interaction with Pin1. Proc Natl Acad Sci U S A (2010) 1.57
c-Myc-induced transcription factor AP4 is required for host protection mediated by CD8+ T cells. Nat Immunol (2014) 1.57
Efficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer. Clin Cancer Res (2013) 1.56
Direct interaction between the inhibitor 2 and ceramide via sphingolipid-protein binding is involved in the regulation of protein phosphatase 2A activity and signaling. FASEB J (2008) 1.56
Phosphorylation regulates c-Myc's oncogenic activity in the mammary gland. Cancer Res (2011) 1.54
HOXB7 Is an ERα Cofactor in the Activation of HER2 and Multiple ER Target Genes Leading to Endocrine Resistance. Cancer Discov (2015) 1.54
Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res (2010) 1.47
Combined Inactivation of MYC and K-Ras oncogenes reverses tumorigenesis in lung adenocarcinomas and lymphomas. PLoS One (2008) 1.46
Peptidyl-prolyl isomerase 1 (Pin1) serves as a coactivator of steroid receptor by regulating the activity of phosphorylated steroid receptor coactivator 3 (SRC-3/AIB1). Mol Cell Biol (2005) 1.45
Phosphoproteomic analysis reveals Smarcb1 dependent EGFR signaling in Malignant Rhabdoid tumor cells. Mol Cancer (2015) 1.42
MYC degradation. Cold Spring Harb Perspect Med (2014) 1.42
Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia (2006) 1.41
Pim1 kinase synergizes with c-MYC to induce advanced prostate carcinoma. Oncogene (2010) 1.39
The Kaposi's sarcoma-associated herpesvirus LANA protein stabilizes and activates c-Myc. J Virol (2007) 1.36
Phosphorylation by Cdk2 is required for Myc to repress Ras-induced senescence in cotransformation. Proc Natl Acad Sci U S A (2009) 1.36
Preventing the degradation of mps1 at centrosomes is sufficient to cause centrosome reduplication in human cells. Mol Biol Cell (2007) 1.34
Balance of Yin and Yang: ubiquitylation-mediated regulation of p53 and c-Myc. Neoplasia (2006) 1.34
The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J (2009) 1.33
Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors. Mol Cancer (2006) 1.33
Functional proteomics can define prognosis and predict pathologic complete response in patients with breast cancer. Clin Proteomics (2011) 1.32
Dysfunctional oxidative phosphorylation makes malignant melanoma cells addicted to glycolysis driven by the (V600E)BRAF oncogene. Oncotarget (2013) 1.32
MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase. Cancer Res (2011) 1.32
Myc degradation: dancing with ubiquitin ligases. Proc Natl Acad Sci U S A (2004) 1.31
Subcellular localization of glycogen synthase kinase 3beta controls embryonic stem cell self-renewal. Mol Cell Biol (2009) 1.31
Degradation of the tumor suppressor PML by Pin1 contributes to the cancer phenotype of breast cancer MDA-MB-231 cells. Mol Cell Biol (2007) 1.27
Inhibition of HMGcoA reductase by atorvastatin prevents and reverses MYC-induced lymphomagenesis. Blood (2007) 1.27
Molecular characterization of spontaneous mesenchymal stem cell transformation. PLoS One (2008) 1.26
Targeting c-MYC by antagonizing PP2A inhibitors in breast cancer. Proc Natl Acad Sci U S A (2014) 1.25
Regulation of the Warburg effect in early-passage breast cancer cells. Neoplasia (2008) 1.23
Pin1 regulates centrosome duplication, and its overexpression induces centrosome amplification, chromosome instability, and oncogenesis. Mol Cell Biol (2006) 1.21
Kinase and BET Inhibitors Together Clamp Inhibition of PI3K Signaling and Overcome Resistance to Therapy. Cancer Cell (2015) 1.21
MicroRNA-223 functions as an oncogene in human gastric cancer by targeting FBXW7/hCdc4. J Cancer Res Clin Oncol (2012) 1.21
Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev (2013) 1.18
Phenothiazines induce PP2A-mediated apoptosis in T cell acute lymphoblastic leukemia. J Clin Invest (2014) 1.17
Molecular requirements for transformation of fallopian tube epithelial cells into serous carcinoma. Neoplasia (2011) 1.17
Defining the cooperative genetic changes that temporally drive alveolar rhabdomyosarcoma. Cancer Res (2008) 1.16
Mechanistic insight into Myc stabilization in breast cancer involving aberrant Axin1 expression. Proc Natl Acad Sci U S A (2011) 1.16
Epigenetic responses to environmental change and their evolutionary implications. Philos Trans R Soc Lond B Biol Sci (2009) 1.14
A tumor suppressor role for PP2A-B56alpha through negative regulation of c-Myc and other key oncoproteins. Cancer Metastasis Rev (2008) 1.14
Merkel cell polyomavirus large T antigen has growth-promoting and inhibitory activities. J Virol (2013) 1.14
Mechanism for inactivation of the mitotic inhibitory kinase Wee1 at M phase. Proc Natl Acad Sci U S A (2007) 1.13
AMBRA1 and BECLIN 1 interplay in the crosstalk between autophagy and cell proliferation. Cell Cycle (2015) 1.13
Survival signals generated by estrogen and phospholipase D in MCF-7 breast cancer cells are dependent on Myc. Mol Cell Biol (2005) 1.12
Cdk2 and Pin1 negatively regulate the transcriptional corepressor SMRT. J Cell Biol (2008) 1.12
Regulation of the ring finger E3 ligase Siah2 by p38 MAPK. J Biol Chem (2006) 1.11
Transient structure and dynamics in the disordered c-Myc transactivation domain affect Bin1 binding. Nucleic Acids Res (2012) 1.10
Peptidyl-prolyl cis/trans isomerase Pin1 is critical for the regulation of PKB/Akt stability and activation phosphorylation. Oncogene (2009) 1.10
Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability. Mol Cancer (2008) 1.09
Protein phosphatase 2A negatively regulates eukaryotic initiation factor 4E phosphorylation and eIF4F assembly through direct dephosphorylation of Mnk and eIF4E. Neoplasia (2010) 1.09
Phosphoinositide 3-kinase activation in late G1 is required for c-Myc stabilization and S phase entry. Mol Cell Biol (2006) 1.07
Peptidyl-prolyl cis/trans isomerases and transcription: is there a twist in the tail? EMBO Rep (2007) 1.07
CSN6 drives carcinogenesis by positively regulating Myc stability. Nat Commun (2014) 1.06
Creating oral squamous cancer cells: a cellular model of oral-esophageal carcinogenesis. Proc Natl Acad Sci U S A (2005) 1.05
MEK/ERK inhibitor U0126 increases the radiosensitivity of rhabdomyosarcoma cells in vitro and in vivo by downregulating growth and DNA repair signals. Mol Cancer Ther (2011) 1.05
Regulation of the sphingosine-recycling pathway for ceramide generation by oxidative stress, and its role in controlling c-Myc/Max function. Biochem J (2006) 1.04
MYC/MAX control ERK signaling and pluripotency by regulation of dual-specificity phosphatases 2 and 7. Genes Dev (2013) 1.04
Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC. Mol Cell (2011) 1.03
ReSETting PP2A tumour suppressor activity in blast crisis and imatinib-resistant chronic myelogenous leukaemia. Br J Cancer (2006) 1.03
Sensing and integration of Erk and PI3K signals by Myc. PLoS Comput Biol (2008) 1.03
Pin1 catalyzes conformational changes of Thr-187 in p27Kip1 and mediates its stability through a polyubiquitination process. J Biol Chem (2009) 1.03
New strategies in neuroblastoma: Therapeutic targeting of MYCN and ALK. Clin Cancer Res (2013) 1.02
FRA1 is a determinant for the difference in RAS-induced transformation between human and rat fibroblasts. Proc Natl Acad Sci U S A (2006) 1.02
ELR+ CXC chemokines and oncogenic Ras-mediated tumorigenesis. Carcinogenesis (2009) 1.02
Prolyl isomerase Pin1 in cancer. Cell Res (2014) 1.01
Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis. Mol Cell Biol (2013) 1.01
Targeting inhibitors of the tumor suppressor PP2A for the treatment of pancreatic cancer. Mol Cancer Res (2014) 1.01
Mechanisms of c-myc degradation by nickel compounds and hypoxia. PLoS One (2009) 0.99
G protein-coupled receptor kinase 2 (GRK2) modulation and cell cycle progression. Proc Natl Acad Sci U S A (2009) 0.99
Protein phosphatase 2A stabilizes human securin, whose phosphorylated forms are degraded via the SCF ubiquitin ligase. Mol Cell Biol (2006) 0.99
Pin1 associates with and induces translocation of CRTC2 to the cytosol, thereby suppressing cAMP-responsive element transcriptional activity. J Biol Chem (2010) 0.99
Hyperphosphorylation regulates the activity of SREBP1 during mitosis. Proc Natl Acad Sci U S A (2005) 0.98
Myc stabilization in response to estrogen and phospholipase D in MCF-7 breast cancer cells. FEBS Lett (2006) 0.98
Oncogenic pathway signatures in human cancers as a guide to targeted therapies. Nature (2005) 19.56
A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell (2006) 18.81
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature (2010) 14.62
BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell (2011) 14.34
Transformation from committed progenitor to leukaemia stem cell initiated by MLL-AF9. Nature (2006) 11.90
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
Phosphoproteome analysis by mass spectrometry and its application to Saccharomyces cerevisiae. Nat Biotechnol (2002) 8.37
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Lentivirus-delivered stable gene silencing by RNAi in primary cells. RNA (2003) 8.07
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Retracted Genomic signatures to guide the use of chemotherapeutics. Nat Med (2006) 7.45
Gene expression predictors of breast cancer outcomes. Lancet (2003) 6.99
Retracted A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med (2006) 6.69
Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells. Cell (2009) 6.55
The Ca2+/calmodulin-dependent protein kinase kinases are AMP-activated protein kinase kinases. J Biol Chem (2005) 6.27
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Systems biology of vaccination for seasonal influenza in humans. Nat Immunol (2011) 6.09
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
The program of androgen-responsive genes in neoplastic prostate epithelium. Proc Natl Acad Sci U S A (2002) 5.98
Minimizing the risk of reporting false positives in large-scale RNAi screens. Nat Methods (2006) 5.96
Retracted An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer. J Clin Oncol (2007) 5.77
Profiling critical cancer gene mutations in clinical tumor samples. PLoS One (2009) 5.63
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
CIP2A inhibits PP2A in human malignancies. Cell (2007) 5.28
A public genome-scale lentiviral expression library of human ORFs. Nat Methods (2011) 4.98
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Feedback circuit among INK4 tumor suppressors constrains human glioblastoma development. Cancer Cell (2008) 4.71
AKT-independent signaling downstream of oncogenic PIK3CA mutations in human cancer. Cancer Cell (2009) 4.71
Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell (2006) 4.68
FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J Exp Med (2007) 4.59
Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell (2006) 4.52
Regulation of in situ to invasive breast carcinoma transition. Cancer Cell (2008) 4.46
Young age at diagnosis correlates with worse prognosis and defines a subset of breast cancers with shared patterns of gene expression. J Clin Oncol (2008) 4.45
The JAK2/STAT3 signaling pathway is required for growth of CD44⁺CD24⁻ stem cell-like breast cancer cells in human tumors. J Clin Invest (2011) 4.41
The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth. PLoS One (2008) 4.32
Distinct requirements for Ras oncogenesis in human versus mouse cells. Genes Dev (2002) 4.30
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev (2007) 4.25
Aurora B phosphorylates centromeric MCAK and regulates its localization and microtubule depolymerization activity. Curr Biol (2004) 4.20
From promiscuity to precision: protein phosphatases get a makeover. Mol Cell (2009) 4.17
Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer. Proc Natl Acad Sci U S A (2011) 4.15
Genome-scale loss-of-function screening with a lentiviral RNAi library. Nat Methods (2006) 4.12
Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med (2002) 4.04
High-Dimensional Sparse Factor Modeling: Applications in Gene Expression Genomics. J Am Stat Assoc (2008) 3.92
Immortalization and transformation of primary human airway epithelial cells by gene transfer. Oncogene (2002) 3.80
Gene expression phenotypic models that predict the activity of oncogenic pathways. Nat Genet (2003) 3.78
Midzone activation of aurora B in anaphase produces an intracellular phosphorylation gradient. Nature (2008) 3.77
Protein architecture of the human kinetochore microtubule attachment site. Cell (2009) 3.68
Retracted Validation of gene signatures that predict the response of breast cancer to neoadjuvant chemotherapy: a substudy of the EORTC 10994/BIG 00-01 clinical trial. Lancet Oncol (2007) 3.67
The dissociation of cohesin from chromosomes in prophase is regulated by Polo-like kinase. Mol Cell (2002) 3.65
Chemosensitivity linked to p73 function. Cancer Cell (2003) 3.63
Blood vessels engineered from human cells. Lancet (2005) 3.61
Emerging insights into the molecular and cellular basis of glioblastoma. Genes Dev (2012) 3.44
Human mammary epithelial cell transformation through the activation of phosphatidylinositol 3-kinase. Cancer Cell (2003) 3.33
β-Catenin-driven cancers require a YAP1 transcriptional complex for survival and tumorigenesis. Cell (2012) 3.33
A pathway-based classification of human breast cancer. Proc Natl Acad Sci U S A (2010) 3.30
Identification of specific PP2A complexes involved in human cell transformation. Cancer Cell (2004) 3.29
Telomerase maintains telomere structure in normal human cells. Cell (2003) 3.29
Retracted Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer. JAMA (2008) 3.26
Identification of genotype-selective antitumor agents using synthetic lethal chemical screening in engineered human tumor cells. Cancer Cell (2003) 3.23
Aurora B is enriched at merotelic attachment sites, where it regulates MCAK. Curr Biol (2006) 3.22
GATHER: a systems approach to interpreting genomic signatures. Bioinformatics (2006) 3.22
Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. Nat Genet (2013) 3.19
Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell (2005) 3.17
Inhibition of aurora B kinase blocks chromosome segregation, overrides the spindle checkpoint, and perturbs microtubule dynamics in mitosis. Curr Biol (2002) 3.17
Mechanism of Aurora B activation by INCENP and inhibition by hesperadin. Mol Cell (2005) 3.14
Histone H3 Thr-3 phosphorylation by Haspin positions Aurora B at centromeres in mitosis. Science (2010) 3.13
An oncogene-tumor suppressor cascade drives metastatic prostate cancer by coordinately activating Ras and nuclear factor-kappaB. Nat Med (2010) 3.09
An E2F1-dependent gene expression program that determines the balance between proliferation and cell death. Cancer Cell (2008) 3.07
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A (2012) 3.06
Hypothalamic CaMKK2 contributes to the regulation of energy balance. Cell Metab (2008) 3.04
The highly conserved Ndc80 complex is required for kinetochore assembly, chromosome congression, and spindle checkpoint activity. Genes Dev (2003) 3.04
An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA. Nature (2009) 3.04
A genetically defined model for human ovarian cancer. Cancer Res (2004) 3.02
The prolyl isomerase Pin1 reveals a mechanism to control p53 functions after genotoxic insults. Nature (2002) 3.02
Making sense of cancer genomic data. Genes Dev (2011) 3.01
The prolyl isomerase Pin1 is a regulator of p53 in genotoxic response. Nature (2002) 2.94
A bistable Rb-E2F switch underlies the restriction point. Nat Cell Biol (2008) 2.91
An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells. Cancer Cell (2010) 2.85
Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci U S A (2002) 2.82
E2Fs link the control of G1/S and G2/M transcription. EMBO J (2004) 2.81
Retracted Pharmacogenomic strategies provide a rational approach to the treatment of cisplatin-resistant patients with advanced cancer. J Clin Oncol (2007) 2.80
Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol (2007) 2.76
Integrated modeling of clinical and gene expression information for personalized prediction of disease outcomes. Proc Natl Acad Sci U S A (2004) 2.74
Growth arrest and DNA damage-inducible protein GADD34 targets protein phosphatase 1 alpha to the endoplasmic reticulum and promotes dephosphorylation of the alpha subunit of eukaryotic translation initiation factor 2. Mol Cell Biol (2003) 2.70
Interplay between oncogene-induced DNA damage response and heterochromatin in senescence and cancer. Nat Cell Biol (2011) 2.69
Induction of spine growth and synapse formation by regulation of the spine actin cytoskeleton. Neuron (2004) 2.68
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell (2010) 2.68
A two-stage, p16(INK4A)- and p53-dependent keratinocyte senescence mechanism that limits replicative potential independent of telomere status. Mol Cell Biol (2002) 2.66
Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway. PLoS Genet (2012) 2.63
Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res (2005) 2.63
Divergent roles for RalA and RalB in malignant growth of human pancreatic carcinoma cells. Curr Biol (2006) 2.61
Bone formation by human postnatal bone marrow stromal stem cells is enhanced by telomerase expression. Nat Biotechnol (2002) 2.61
Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell (2002) 2.56
Fatty acid synthase: a metabolic enzyme and candidate oncogene in prostate cancer. J Natl Cancer Inst (2009) 2.53